Tailored human biospecimens for biomedical discovery

AMSBIO has broadened its biofluid collection and processing capabilities, now offering an extensive range of ethically sourced, customisable human blood biospecimens from both healthy and disease-state donors to support cutting-edge biomedical research.

Drawing on a diverse network of donors, AMSBIO provides high-quality samples tailored to specific demographic profiles, volumes, and processing protocols. The company’s fully licensed collection and processing facility ensures complete traceability and regulatory compliance at every step.

The expanded portfolio includes leukopaks, plasma, serum, whole blood, peripheral blood mononuclear cells (PBMCs), and isolated immune cells, each prepared to meet strict research specifications.

Unlike conventional blood banks, AMSBIO offers researchers enhanced flexibility in donor selection and consent processes - making it possible to source fully authorised samples for commercial use in applications such as drug development, cell therapy, and regenerative medicine.

Designed to accelerate research across oncology, autoimmune disorders, neurodegeneration, and other therapeutic areas, AMSBIO biospecimens provide access to well-characterised donor cohorts that align closely with study requirements.

In addition to its expanded offering, AMSBIO now provides rapid processing and overnight delivery of fresh, custom-prepared biofluids across Europe. Plans are also in place to extend this service to North America, widening access to its bespoke collection capabilities.

With decades of experience in biospecimen handling, AMSBIO remains a trusted partner for high-quality biofluid sourcing, committed to precision, compliance, and scientific excellence.

More information online